Treatment of Netherton Syndrome With Abrocitinib

Abstract

This case report describes a 28-year-old woman with Netherton syndrome who had large erythematous migratory patches with serpiginous double-edged scales on her face, neck, trunk, and extremities.

Abrocitinib as a Novel Treatment for Multiple Skin Disorders: 3 Case Reports and a Scoping Review

“… 2 Additionally, a patient with Netherton syndrome experienced a recurrence within a week of discontinuing dupilumab. 11 Notably, both patients achieved rapid and complete remission after switching to abrocitinib treatment. AA, whether occurring alone, 5 comorbid with AD, 3 , 7 or induced by drugs 6 that have failed to respond to other therapies, all showed significant improvement with abrocitinib treatment.…”

“… 15 In this scoping review, 2 of 28 patients (7.1%) experienced mild common AEs while initiating treatment with abrocitinib 200 mg daily, but had no AEs when the dosage was tapered to 100 mg daily. 10 , 11 …”

“…These mainly include lichen sclerosus (10 cases), 4 AA (5 cases), 3,[5][6][7] and lichenoid amyloidosis (2 cases). 1 Additionally, other treated conditions encompassed eruptive pruritic papular porokeratosis, 8 Hailey-Hailey disease, 9 necrobiosis lipoidica, 10 occupational airborne allergic contact dermatitis, 2 Netherton syndrome, 11 oral lichen planus, 12 nipple and areola eczema, 13 prurigo nodularis, 14 PG, LV, and HS, each presenting 1 case. Patients who had previously failed to respond to traditional medicines and/or biological agents (such as secukinumab and dupilumab) achieved substantial clinical improvement within a median of 12 weeks (range 3-96) after abrocitinib monotherapy or in combination with other medications.…”